Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax (2022 - 2026)

Centessa Pharmaceuticals (CNTA) has 5 years of Long-Term Deferred Tax data on file, last reported at $24.2 million in Q1 2026.

• Quarterly Long-Term Deferred Tax fell 8.41% year-over-year to $24.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (down 8.41% YoY) and the FY2025 annual result came in at $24.8 million, down 6.8% from the prior year.
• Long-Term Deferred Tax slipped to $24.2 million in Q1 2026 per CNTA's latest filing, from $24.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $29.6 million in Q4 2023 and bottomed at $3.5 million in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $26.6 million (2024), against an average of $25.1 million.
• The widest annual swing landed in 2023, when Long-Term Deferred Tax surged 744.16%; it then slipped 11.27% in 2025.
• Tracing CNTA's Long-Term Deferred Tax over 5 years: stood at $3.5 million in 2022, then surged by 744.16% to $29.6 million in 2023, then decreased by 10.32% to $26.6 million in 2024, then declined by 6.8% to $24.8 million in 2025, then dropped by 2.45% to $24.2 million in 2026.
• Per Business Quant, the three latest CNTA Long-Term Deferred Tax figures stand at $24.2 million (Q1 2026), $24.8 million (Q4 2025), and $25.0 million (Q3 2025).

Peer Comparison